SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory and infectious diseases, today announced detailed results ...

The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...

WWE Hall of Famer Ric Flair is cancer free once again. Flair announced on Tuesday that he's completed his treatment for ...

BMO Capital Markets pointed to FDA leadership, and CBER Director Vinay Prasad in particular, as potential factors in the ...

SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...

Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

The FDA has rejected Replimune’s request for approval of RP1, adding the melanoma drug candidate to the list of assets to ...

Scancell Holdings plc (AIM: SCLP), the developer of Immunobody ® and Moditope ® active immunotherapies to treat cancer, announces further positive data from the ongoing Phase 2 SCOPE trial of ...

Similarly to how students need to go to the nurse's office if they want ibuprofen, they also cannot bring their own bottle of ...

Earlier this summer, wrestling icon Ric Flair announced that he was battling skin cancer. Flair, 76, has dealt with a litany ...